Drug intelligence / Profile preview

amcenestrant + letrozole

Development stage: Discontinued
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Amcenestrant + letrozole refers to a combination therapy that was studied in clinical trials. Amcenestrant is an oral selective estrogen receptor degrader (SERD) that works by serving as a competitive antagonist to the estrogen receptor, inducing conformational changes that lead to degradation of the receptors. Letrozole is an aromatase inhibitor that reduces estrogen production. This combination was investigated for the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.

Targets

ER (Estrogen receptor)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on amcenestrant + letrozole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amcenestrant + letrozole.

Explore the full profile